TerrAscend Corp.

TSX:TSND.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.52 -1.61%

-$0.02 today

Market cap
$193.65M
Beta
2.04
P/E (TTM)
-2.5
EPS (TTM)
-$0.26
52W Low $0.33High $2.00

Volume 0.26M

Average 0.31M

TSND.TO EBITDA Margin

EBITDA as a percentage of revenue.

TerrAscend Corp.TSX: TSND.TO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 24.5%

EBITDA Margin was 24.5% in Q1 FY2026, up 5.9 pp from a year earlier. On a trailing-twelve-month basis it was 23.1%, up 19.6 pp year over year. Over 3 fiscal years it widened by 126.3 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 13.2% for the fiscal year ending Dec 2026, down from 23.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
24.5%+2.5 pp QoQ
Last fiscal yearDec 2025
23.7%+21.7 pp YoY
LTMMar 2026
23.1%+19.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.9 pp-8.1 pp-14.0 pp
1 year+21.7 pp-10.5 pp-32.2 pp
3 years+126.3 pp-8.7 pp-134.9 pp
5 years-7.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
23.7%
Year-over-year change
+21.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TSND.TO compares with its peers on the latest reported figures

  • TSND.TO's LTM Mar 2026 EBITDA Margin of 23.1% is the 5th highest of the 9 companies compared; the peer median is 13.9%.
  • Its year-over-year change of +19.6 pp is the 3rd highest of 9, against a peer median of +5.6 pp.
  • Over three fiscal years its change of +126.3 pp compares with a peer median of +39.6 pp.
TSND.TO Competitors Peer median
EBITDA Margin for TSND.TO and competitors
Company Period LTM level YoY 3-year change
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 202649.3% +16.9 pp-11.3 pp
HLS.TOHLS Therapeutics Inc.LTM Mar 202631.9% +6.2 pp+2.6 pp
XLY.TOAuxly Cannabis Group Inc.LTM Mar 202631.0% +5.0 pp+133.5 pp
DR.TOMedical Facilities CorporationLTM Mar 202624.7% -1.0 pp+10.9 pp
TSND.TOTerrAscend Corp.LTM Mar 202623.1% +19.6 pp+126.3 pp
ACB.TOAurora Cannabis Inc.LTM Mar 20263.1% -11.9 pp+39.6 pp
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026-10.5% +23.0 pp+1464.5 pp
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-14.9% -18.5 pp—
WEED.TOCanopy Growth CorporationLTM Mar 2026-20.4% +157.8 pp+798.1 pp
EPRX.TOEupraxia Pharmaceuticals Inc.FY2025— ——
Peer median (excluding TSND.TO) 13.9%+5.6 pp+39.6 pp

Competitors are the stored peer set for TSND.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.36M240.45M317.33M306.68M265.12M
Cost of Revenue109.32M203.35M112.49M156.72M131.93M
Gross Profit134.04M119.74M138.02M149.96M133.19M
Gross Margin55.1%49.8%43.5%48.9%50.2%
Research & Development00000
Selling, General & Admin73.71M116.64M112.17M111.33M82.41M
Operating Expenses94.12M150.69M179.56M167.07M87.78M
Depreciation & Amortization13.63M24.6M22.7M22.99M17.51M
EBITDA44.96M(246.52M)(1.03M)6.16M62.92M
EBITDA Margin18.5%-102.5%-0.3%2.0%23.7%
Operating Income31.33M(23.04M)(19.87M)(17.11M)45.41M
Operating Margin12.9%-9.6%-6.3%-5.6%17.1%
Interest Income00000
Interest Expense24.57M37.9M35.11M35.4M36.93M
Other Income / Expenses12.46M(277.92M)(38.97M)(35.13M)(40.34M)
Income Before Tax43.78M(300.95M)(58.83M)(52.23M)5.06M
Pre-Tax Margin18.0%-125.2%-18.5%-17.0%1.9%
Income Tax Expense28.88M(10.46M)23.45M20.44M29.98M
Net Income3.06M(303.96M)(91.1M)(80.23M)(87.74M)
Net Margin1.3%-126.4%-28.7%-26.2%-33.1%
EPS (Basic)0.07(1.31)(0.32)(0.28)(0.29)
EPS (Diluted)0.01(1.31)(0.32)(0.28)(0.29)
Weighted Avg Shares181.06M244.35M279.29M291.51M301.08M
Weighted Avg Shares (Diluted)208.71M244.35M279.29M291.51M301.08M

TerrAscend Corp.

TSX:TSND.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.